CARLOS ARTEAGA and FREDERICK ALT were named the winners of the 2015 Prize for Scientific Excellence by the American-Italian Cancer Foundation.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
